[Optimizing antidepressant pharmacotherapy in a case of inflammatory bowel disease and major depression].
In the framework of a case report on a patient suffering from major depression and inflammatory bowel disease we address the pharmacotherapeutical options in case of subtherapeutic mirtazapine levels. We applied therapeutic drug monitoring (TDM) and cytochrome P450 2D6 genotyping, and switched to an orodispersible tablet. Thus, mirtazapine plasma levels could be raised and clinical improvement of the depressive symptoms was achieved.